GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Alvotech
Alvotech is an Icelandic biopharmaceutical company specializing in the development and production of biosimilars (copies of complex biological drugs). Its share price is dependent on its success in obtaining regulatory approvals and competition in the biosimilar market.
Share prices of companies in the market segment - Pharma other
Alvotech is a biopharmaceutical company specializing in the development and production of biosimilars (analogs of complex biological drugs). We classify it in the Pharma Other sector, and the chart below reflects the dynamics of this growing segment, which is aimed at competing with original blockbusters.
Broad Market Index - GURU.Markets
Alvotech is an Icelandic biopharmaceutical company specializing in the development and production of biosimilars (analogs of biological drugs). Its strategy makes it a prominent player in the GURU.Markets index. The chart below represents the entire market. Find out how Alvotech compares to it.
Change in the price of a company, segment, and market as a whole per day
ALVO - Daily change in the company's share price Alvotech
Shares of Alvotech, a biopharmaceutical company specializing in biosimilars, are highly volatile. Change_co measures market reaction to news of the approval and launch of similar products to expensive biologics. This metric is an important component of the formulas on System.GURU.Markets, which assess the risks and potential in this niche of the pharmaceutical industry.
Daily change in the price of a set of shares in a market segment - Pharma other
The biosimilars sector, in which Alvotech operates, is highly dynamic. This chart reflects the average volatility of the pharmaceutical industry. It serves as a benchmark for assessing how sensitive Alvotech's blockbuster analog business is to general trends and patent disputes.
Daily change in the price of a broad market stock, index - GURU.Markets
Alvotech is an Icelandic biopharmaceutical company specializing in the development and production of biosimilars (analogs of biological drugs). The chart below shows volatility in the biotech sector, providing context for analyzing Alvotech stock.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Alvotech
Alvotech is a biopharmaceutical company specializing in the development and production of biosimilarsāmore affordable alternatives to expensive biotech drugs. Its year-over-year performance reflects its success in obtaining approvals for its products and its ability to compete with pharmaceutical giants.
Annual dynamics of market capitalization of the market segment - Pharma other
Alvotech is a biopharmaceutical company focused exclusively on the development and production of biosimilars (analogs of biological drugs). Its success depends on its ability to successfully launch lower-cost versions of expensive drugs. The chart below shows how its unique niche strategy is working in the pharmaceutical sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Alvotech, which specializes in developing biosimilars (analogs of expensive biologics), is a growth story in the pharmaceutical industry. Its stock price depends on its success in securing approvals and competing with brand-name drugs. The chart is a bet on cheaper drugs gaining market share.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Alvotech
Alvotech, a biopharmaceutical company specializing in the development and production of biosimilars (analogs of complex biologics), has monthly fluctuations reflecting news of regulatory approvals for its products and successes in patent disputes with original drug manufacturers.
Monthly dynamics of market capitalization of the market segment - Pharma other
Alvotech is a biopharmaceutical company focused exclusively on the development and production of biosimilarsāmore affordable versions of complex biological drugs. Its success depends on regulatory approvals and competition. The pharmaceutical sector dynamics chart will highlight general trends that can be used to assess the potential of Alvotech's business model, which is focused on drug accessibility.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Alvotech is an Icelandic biotechnology company focused exclusively on the development and production of biosimilars (analogs of complex biological drugs). Given the market trends shown in the chart, Alvotech's performance is driven by its success in obtaining regulatory approvals and competition in the biosimilar market, rather than by general sentiment.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Alvotech
Alvotech, a biopharmaceutical company specializing in biosimilars, has seen its weekly performance heavily dependent on regulatory news. FDA approvals of its expensive brand-name drug analogs and patent disputes have caused sharp price fluctuations, reflecting the high stakes in this niche.
Weekly dynamics of market capitalization of the market segment - Pharma other
Alvotech, operating in the narrow niche of biosimilars, can move independently of the broader pharmaceutical sector. While the industry reacts to general news, Alvotech shares rise or fall based on regulatory decisions regarding its specific drugs. The chart clearly demonstrates how often the company's performance takes on a life of its own, disconnected from overall trends.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Alvotech specializes in developing biosimilarsāanalogs of expensive biotech drugs. Its success depends on regulatory approvals and patent disputes, not the state of the economy. The chart shows how the company's shares are operating independently, defying general market trends.
Market capitalization of the company, segment and market as a whole
ALVO - Market capitalization of the company Alvotech
Alvotech's market capitalization reflects investor hopes for the biosimilar marketāmore affordable alternatives to expensive biological drugs. Its volatility is driven by news about clinical trials and regulatory approvals. The company's valuation reflects a bet on its ability to successfully launch its products and challenge pharmaceutical giants.
ALVO - Share of the company's market capitalization Alvotech within the market segment - Pharma other
Alvotech specializes in the development and production of biosimilarsāanalogs of expensive biological drugs. Its market share reflects its strategy of creating affordable drugs, which could challenge established leaders in the treatment of autoimmune diseases.
Market capitalization of the market segment - Pharma other
The chart below shows the market capitalization of the fast-growing biosimilars sectorāanalogs of expensive biotech drugs. Alvotech is a clear bet on this market. Its potential explosive growth, which you can see in the chart, is linked to the expiration of patents on blockbuster drugs, and Alvotech aims to be one of the main beneficiaries of this process.
Market capitalization of all companies included in a broad market index - GURU.Markets
Alvotech develops biosimilarsāmore affordable alternatives to expensive biologics. The company's market capitalization is driven by lowering treatment costs worldwide and increasing access to medicine. The chart below shows the economic weight of a business that makes treatments cheaper for millions.
Book value capitalization of the company, segment and market as a whole
ALVO - Book value capitalization of the company Alvotech
Alvotech's foundation is its modern biopharmaceutical production facilities and R&D centers, designed to develop and produce biosimilarsāmore affordable versions of complex biological drugs. The chart shows how capital-intensive investments in plant and laboratory construction provide the financial basis for competing with pharmaceutical giants.
ALVO - Share of the company's book capitalization Alvotech within the market segment - Pharma other
Alvotech is challenging pharmaceutical giants by developing biosimilars, and this requires a robust manufacturing base. The chart shows the company's share of real assetsāits state-of-the-art factories and laboratories. This is the material foundation that allows it to compete in the capital-intensive world of biotechnology.
Market segment balance sheet capitalization - Pharma other
Alvotech isn't just an R&D company, but a biosimilars manufacturer, making it quite capital-intensive for its segment. Creating complex biologics requires massive investments in factories and ultra-clean production lines. A chart of the pharmaceutical sector's book value shows that Alvotech is a heavyweight in terms of assets.
Book value of all companies included in the broad market index - GURU.Markets
Alvotech's balance sheet reflects its colossal investments in biosimilar drug development. Its assets include more than just laboratories, but sophisticated production facilities and a portfolio of intellectual property. The chart shows the capital required to compete in the global pharmaceutical market and make medicines more accessible.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Alvotech
Alvotech operates in the biosimilars sector, where the primary value lies not in its manufacturing plants but in its intellectual property: patents and clinical developments. Its market valuation significantly exceeds its book value, as investors factor in future revenues from the successful launch of more affordable analogs of expensive drugs. The chart is a barometer of faith in its R&D.
Market to book capitalization ratio in a market segment - Pharma other
Alvotech is a biopharmaceutical company whose core value lies in its laboratories: patents and scientific research. This chart shows how much the market valuation of its intellectual capital exceeds the value of its physical equipment. This is investors betting on the success of future drugs, not on current tangible assets.
Market to book capitalization ratio for the market as a whole
Alvotech is a biopharmaceutical company whose value lies in its research and patents, not its manufacturing plants. The market values āāits future potential, not its current tangible assets. This chart demonstrates the premium investors are willing to pay for medical innovation compared to the overall economy.
Debts of the company, segment and market as a whole
ALVO - Company debts Alvotech
Biopharmaceutical company Alvotech is focused on developing biosimilars, a process that requires significant and long-term investment in research. Debt financing is a vital bridge, allowing the company to continue clinical trials until products are brought to market and generate revenue.
Market segment debts - Pharma other
Alvotech is a biopharmaceutical company whose business requires significant investment in research and clinical trials long before revenue is generated. Debt in this sector often reflects the stage of development and investor confidence. This chart demonstrates the company's preferred source of R&D funding: shareholder dilution or debt.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Alvotech
Alvotech specializes in the development and production of biosimilarsāmore affordable alternatives to expensive biologic drugs. This chart shows how the company finances its complex and capital-intensive manufacturing processes. The debt level here reflects its investments in plant construction and clinical trials to bring its products to the global market.
Market segment debt to market segment book capitalization - Pharma other
Alvotech operates in the biopharmaceutical industry, where debt is often used to finance lengthy and expensive clinical trials. This chart provides a financial health barometer for the entire biosimilars segment. It allows one to assess whether Alvotech's debt load is typical for companies at a similar stage of development and research.
Debt to book value of all companies in the market
Biopharmaceutical company Alvotech requires significant capital for research. This chart is a barometer of the overall state of the debt market. It helps understand how the availability of borrowed funds across the economy impacts the ability of innovative industries like pharmaceuticals to finance their long-term and risky projects.
P/E of the company, segment and market as a whole
P/E - Alvotech
This metric for Alvotech, a biopharmaceutical company, reflects investors' confidence in its future drugs. Since the bulk of profits are still to come, any estimate of current profitability is very high. The chart's movement reflects the market's reaction not to current sales, but to news about trials and potential drug approvals, which could change the financial picture.
P/E of the market segment - Pharma other
This chart reflects the average valuation for the biopharmaceutical sector, where investors often buy into future hopes rather than current profits. For Alvotech, which focuses on biosimilars, this is an important benchmark. It helps understand how the market as a whole assesses the risks and potential of companies whose revenues depend on successful developments and regulatory approvals.
P/E of the market as a whole
Alvotech, a biopharmaceutical company, is focused on developing biosimilars, which requires massive investment and faith in future success. This chart serves as a barometer of investor risk appetite. During periods of market optimism, it's easier to fund Alvotech's expensive research, but during downturns, it becomes clear whether investors believe in the company's science or are following general sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Alvotech
Alvotech specializes in the development and production of biosimilarsāmore affordable versions of complex biological drugs. The company's valuation is based on expectations of future approvals and successful drug launches. This chart shows analysts' forecasts for future profitability, taking into account patents, competition, and potential sales volume.
%20P%2FE%20Alvotech&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Alvotech&v=1772513480577 "Chart of the company's future (projected) P/E Alvotech")
Future (projected) P/E of the market segment - Pharma other
Alvotech is a biopharmaceutical company focused on the development and production of biosimilarsāaffordable alternatives to complex biological drugs. This comparison provides insight into how investors assess Alvotech's chances of successfully bringing its products to market compared to other pharmaceutical companies. An above-average valuation may reflect confidence in its development pipeline.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-other&v=1772513480618 "Future (projected) P/E graph of the market segment - Pharma other")
Future (projected) P/E of the market as a whole
Alvotech operates in the highly competitive biosimilar marketāanalogs of expensive biotech drugs. The company's success depends on its ability to secure regulatory approvals and bring its products to market. This chart shows the overall market assessment of future revenue, which influences the availability of capital for R&D and the willingness of investors to finance the long and risky drug development process.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513480631 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Alvotech
Alvotech operates in the biosimilars fieldāanalogs of complex biological drugs. The company's financial indicators, presented here, reflect its progress in the development, clinical trials, and market launch of new drugs. Each regulatory approval and sales launch is a key factor influencing the bottom line of this business.
Profit of companies in the market segment - Pharma other
Alvotech specializes in developing biosimilarsāmore affordable alternatives to expensive biotech drugs. But how does this affect the entire industry? This chart shows the overall profitability of the pharmaceutical sector. It helps us understand whether biosimilars are putting real pressure on the margins of major players or whether the market is large enough for everyone.
Overall market profit
Alvotech is a biopharmaceutical company specializing in the development and production of biosimilars (analogs of complex biological drugs). Its business model is aimed at increasing access to medicines and reducing healthcare costs. Against the backdrop of economic cycles, as reflected in this chart, Alvotech is working to meet the long-term need for lower-cost medicines.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Alvotech
Alvotech specializes in biosimilarsāmore affordable alternatives to expensive biotech drugs. The company's profit forecast reflects market expectations regarding the success of its developments, regulatory approvals, and ability to capture market share from established competitors. This chart shows analysts' confidence in the commercial potential of its portfolio.
%20profit%20of%20the%20company%20Alvotech&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Alvotech&v=1772513480740 "Graph of future (projected) profit of the company Alvotech")
Future (predicted) profit of companies in the market segment - Pharma other
Alvotech specializes in the development and production of biosimilarsāmore affordable versions of expensive biologic drugs. The company's success depends on regulatory approval and the speed of drug introduction. This chart shows overall profit forecasts for the pharmaceutical sector. The key question is: can Alvotech, by challenging the giants, capture market share and exceed expectations?
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-other&v=1772513480777 "Graph of future (predicted) profits of companies in a market segment - Pharma other")
Future (predicted) profit of the market as a whole
Alvotech specializes in the development and production of biosimilarsāmore affordable versions of complex biological drugs. The overall market revenue dynamics shown in the graph indirectly impact the healthcare system. During economic growth, access to expensive medications increases, while during recessions, demand for cost-effective solutions like those offered by Alvotech grows.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513480816 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Alvotech
Alvotech specializes in developing biosimilarsāanalogs of expensive biotech drugs. This metric reflects investors' assessment of the potential future revenue from bringing these drugs to market. A high metric, given current modest sales, indicates high hopes for successful approval and commercialization of products in development.
P/S market segment - Pharma other
Alvotech specializes in the development and production of biosimilarsāmore affordable alternatives to complex biological drugs. This chart shows the average pharmaceutical industry valuation relative to revenue. It serves as a benchmark for understanding how the market perceives Alvotech's potential to capture market share from original drugs.
P/S of the market as a whole
Alvotech specializes in the development and production of biosimilarsāmore affordable alternatives to complex biological drugs. The company's success and revenue depend on regulatory approvals and successful product launches. This chart helps investors understand the premium the market is willing to pay for growth potential in biotech compared to average revenue estimates overall.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Alvotech
Alvotech specializes in biosimilarsāmore affordable alternatives to expensive biologics. Its future revenue depends on the successful launch of new products. This chart shows investors' assessment of the company's development pipeline and its ability to compete with pharmaceutical giants by capturing a share of their future sales.
%20P%2FS%20Alvotech&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Alvotech&v=1772513480949 "The graph of the company's future (projected) P/S Alvotech")
Future (projected) P/S of the market segment - Pharma other
Alvotech specializes in the development and production of biosimilarsāanalogs of expensive biological drugs. The company's future hinges on successful clinical trials and the launch of affordable drugs. This chart shows how its future sales expectations compare to those of other pharmaceutical companies, reflecting investor confidence in its scientific pipeline.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20other&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-other&v=1772513481009 "Future (projected) P/S market segment graph - Pharma other")
Future (projected) P/S of the market as a whole
The overall market revenue growth expectations presented in this chart set the tone for the entire pharmaceutical industry. Alvotech, specializing in biosimilarsāmore affordable alternatives to expensive biologicsāis benefiting from the overall growth in healthcare demand. Market optimism is underpinned by the belief that healthcare systems will seek ways to optimize costs.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513481055 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Alvotech
Alvotech is a biopharmaceutical company focused on the development and production of biosimilarsāanalogs of expensive biological drugs. This chart reflects the commercial success of its products. Revenue growth reflects successful sales of biosimilar drugs for the treatment of autoimmune diseases, oncology, and other conditions, making therapy more accessible.
Sales of companies in the market segment - Pharma other
Alvotech specializes in developing biosimilarsāmore affordable analogues of complex biological drugs. This chart shows the company's market size. Its activities directly impact drug availability and competition in the pharmaceutical industry, and success in bringing new products to market reflects the growth potential of the entire segment.
Overall market sales
Alvotech is a biopharmaceutical company focused on the development and production of biosimilars. While its success depends on specific drugs, the overall economic situation, shown in the graph, influences public and private healthcare funding. Stable economic growth ensures more generous drug budgets, creating demand for its products.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Alvotech
Alvotech specializes in the development and production of biosimilarsāmore affordable versions of complex biological drugs. The company's future sales are directly dependent on successful clinical trials, regulatory approval, and the speed of new drug launches. This chart shows analyst expectations for the commercial potential of Alvotech's development pipeline and its ability to compete with original products.
%20sales%20of%20the%20company%20Alvotech&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Alvotech&v=1772513481223 "Schedule of future (projected) sales of the company Alvotech")
Future (projected) sales of companies in the market segment - Pharma other
Alvotech specializes in the development and production of biosimilarsāmore affordable versions of complex biological drugs. This forecast reflects expectations for the entire biopharmaceutical market. It provides insight into the growth and decline potential analysts see in an industry where competition and innovation drive the success of companies like Alvotech.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-other&v=1772513481255 "Schedule of future (projected) sales of companies in the market segment - Pharma other")
Future (projected) sales of the market as a whole
Alvotech specializes in the development and production of biosimilarsāanalogs of expensive biological drugs. The company's success depends on healthcare systems' commitment to reducing costs. The data in the graph, reflecting the overall economic situation, indirectly impacts healthcare budgets, which determines the speed of adoption of Alvotech's more affordable medications.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513481267 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Alvotech
Alvotech specializes in biosimilarsāmore affordable alternatives to expensive biotech drugs. This chart demonstrates the financial viability of a business model built on competition with pharmaceutical giants. The company's ability to bring new drugs to market and manage complex manufacturing processes determines its bottom line.
Market segment marginality - Pharma other
Alvotech specializes in the development and production of biosimilarsāmore affordable versions of complex biological drugs. Profitability in this niche depends on the success of clinical trials and the speed of product launch. This chart shows the company's operating efficiency compared to other biopharmaceutical manufacturers, reflecting its scientific and commercial potential.
Market marginality as a whole
Alvotech specializes in the development and production of biosimilarsāmore affordable alternatives to expensive biotech drugs. This overall market profitability chart helps assess pricing pressure in the healthcare system. Alvotech's success depends on its ability to offer lower prices while maintaining quality, which is especially important when overall system profitability is declining.
Employees in the company, segment and market as a whole
Number of employees in the company Alvotech
Alvotech specializes in developing biosimilarsāaffordable alternatives to expensive biotech drugs. The graph shows the team of scientists, engineers, and clinicians behind this complex process. Each stage, from research to production, requires unique expertise and directly impacts headcount.
Share of the company's employees Alvotech within the market segment - Pharma other
In the complex biosimilar industry, Alvotech competes on the strength of its scientific and manufacturing capabilities. This metric reflects the company's ability to attract highly qualified specialists in this niche sector. It demonstrates its ability to assemble a significant team of scientists and engineers to develop and commercialize affordable biologics.
Number of employees in the market segment - Pharma other
Alvotech is a biopharmaceutical company specializing in the development and production of biosimilarsāanalogs of complex biological drugs. Its goal is to make advanced medicines more accessible. This chart illustrates the talent pool in the biopharmaceutical sector, showing how growing demand for innovative and affordable medicines is driving job creation.
Number of employees in the market as a whole
Alvotech specializes in biosimilarsāaffordable analogues of complex biotech drugs. Pharmaceuticals is a sector where employment is determined less by current economic conditions than by long-term investments in research. The growth of such companies demonstrates investment in knowledge-intensive talent, which is key to future economic sustainability.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Alvotech (ALVO)
Alvotech is a biopharmaceutical company developing biosimilars of complex drugs. This chart shows how the market values āāscientific potential. The high market capitalization per scientist or engineer reflects the value of intellectual property and the potential for its development, which could capture shares of multi-billion dollar markets upon regulatory approval.
%20of%20the%20company%20Alvotech%20(ALVO)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Alvotech-ALVO&v=1772513481601 "Chart of market capitalization per employee (in thousands of dollars) of the company Alvotech (ALVO)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma other
Alvotech is a biopharmaceutical company specializing in the development and production of biosimilars (complex copies of biotech drugs). It is a research- and capital-intensive business. This chart shows the industry's average market capitalization per employee. It helps investors assess how the market values āāAlvotech's research portfolio and manufacturing capabilities per scientist.
%20by%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-other&v=1772513481643 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma other")
Market capitalization per employee (in thousands of dollars) for the overall market
Alvotech is a biopharmaceutical company specializing in the development and production of biosimilars. This chart shows the market-wide performance metric per employee. This provides insight into how the market values āāAlvotech's research-intensive business, where value is created through research, not just headcount.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513481738 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Alvotech (ALVO)
Alvotech operates in the complex field of biosimilarsācopies of biological drugs. This business requires massive investments in R&D and production, which requires a team of highly qualified scientists. This chart shows how the company moves from burning capital on research to generating sales profits. Efficiency here refers to the ability to scale sales without inflating the staff.
%20Chart%20Alvotech%20(ALVO)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Alvotech-ALVO&v=1772513481764 "Company Profit Per Employee (in thousands of dollars) Chart Alvotech (ALVO)")
Profit per employee (in thousands of dollars) in the market segment - Pharma other
Alvotech is a biotech company focused on biosimilars (analogs of brand-name drugs). This chart shows the benchmark for "Pharma." The average profit per employee in this sector is a balance. "Branded" pharma (R&D) has astronomical profit margins. "Biosimilars" (like Alvotech) are also R&D, but with lower margins. The benchmark averages these models.
%20in%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-other&v=1772513481774 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma other")
Profit per employee (in thousands of dollars) for the market as a whole
Alvotech is a biopharmaceutical company focused on the development and production of biosimilars (analogs of complex biotech drugs). In this industry, profit per employee is an indicator of future success. It can be low or negative during the R&D stage, but it increases sharply once the drugs reach the market. The graph reflects the effectiveness of the transition from research to commercialization.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513481793 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Alvotech (ALVO)
Alvotech is a biopharmaceutical company focused on developing biosimilars. This chart reflects a key stage in the company's life: the transition from capital-intensive research to commercialization. An increase in this indicator indicates that products are beginning to generate revenue, justifying investments in research staff and production.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Alvotech-ALVO&v=1772513481820 "Sales chart per company employee Alvotech (ALVO)")
Sales per employee in the market segment - Pharma other
Alvotech specializes in the development and production of biosimilars (analogs of expensive biologics). This involves complex R&D and high-tech manufacturing. This chart shows the average revenue per employee in this segment. It helps evaluate how productive Alvotech's team (scientists and engineers) is in bringing drugs to market and manufacturing them compared to its biotech competitors.
Sales per employee for the market as a whole
Alvotech specializes in the development and production of biosimilarsāanalogs of complex biotech drugs. It's a knowledge-intensive business. This chart shows how effectively the company utilizes its highly qualified personnel (scientists and engineers) to generate revenue, which is especially important when transitioning from R&D to large-scale commercial production.
Short shares by company, segment and market as a whole
Shares shorted by company Alvotech (ALVO)
Alvotech specializes in biosimilarsāanalogs of complex biotech drugs like Humira. Their success depends entirely on regulatory decisions (like the FDA) and the outcome of costly patent wars with pharmaceutical giants. This chart shows the volume of bets against the company by investors who doubt Alvotech's drug approval or legal success.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Alvotech-ALVO&v=1772513481873 "Short Shares Chart for the Company Alvotech (ALVO)")
Shares shorted by market segment - Pharma other
Alvotech specializes in biosimilarsāmore affordable alternatives to complex biological drugs. Their business model is based on challenging established pharmaceutical blockbusters. This indicator reflects the overall volume of short positions in the biotech sector. An increase in short positions here may indicate that investors perceive risks (such as pricing pressure or approval failures) for the entire industry.
Shares shorted by the overall market
Alvotech (ALVO) is a biopharmaceutical company specializing in the development and production of biosimilars (analogs of complex biological drugs) for the global market. This chart illustrates the overall market pessimism. For a company facing enormous development costs and litigation costs (patent litigation), rising market fear is bad news. It makes it more difficult to raise the capital needed to compete with the giants.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Alvotech (ALVO)
Alvotech (ALVO) is a biopharmaceutical company specializing in the development and production of biosimilars (analogs of complex biological drugs). Their goal is to make expensive drugs affordable. This chart is a momentum oscillator. It helps identify extremes: "overbought" (above 70) on drug approval news or "oversold" (below 30) due to regulatory delays, which is typical for biotech.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Alvotech-ALVO&v=1772513481927 "RSI 14 indicator chart for the company's stock Alvotech (ALVO)")
RSI 14 Market Segment - Pharma other
Alvotech (ALVO) is an Icelandic biotech company specializing in the development and production of "biosimilars"āaffordable alternatives to expensive biologics. This chart tracks overall sentiment in the Pharmaceuticals sector. It helps investors understand whether ALVO's performance reflects its success in drug approvals or whether the overall industry is overheated or oversold.
RSI 14 for the overall market
Alvotech (ALVO) develops biosimilars (copies of complex "live" drugs). This chart shows that its business is betting on savings in healthcare. In times of panic and recession, healthcare systems desperately seek ways to cut costs, which accelerates the transition from expensive brand-name drugs to Alvotech's biosimilars.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ALVO (Alvotech)
Alvotech (ALVO) is an Icelandic biopharmaceutical company focused exclusively on the development and production of biosimilars (analogs of complex biologics). The chart displays the analyst consensus forecast. It shows their assessment of Alvotech's ability to obtain approval and launch a biosimilar of Humira (the world's number one drug) in the US market.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ALVO-Alvotech&v=1772513481966 "A chart showing analyst consensus forecasts for the expected stock price. ALVO (Alvotech)")
The difference between the consensus estimate and the actual stock price ALVO (Alvotech)
Alvotech is an Icelandic biotech company focused entirely on developing and manufacturing biosimilars for top-selling biotech drugs. This chart shows the upside and downside potential analysts see in the stock. It measures the gap between the consensus price forecast and the current price, reflecting their confidence in their portfolio.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ALVO-Alvotech&v=1772513481977 "A chart showing the difference between the consensus forecast and the actual stock price. ALVO (Alvotech)")
Analyst consensus forecast for stock prices by market segment - Pharma other
Alvotech is an Icelandic biotech company focused exclusively on the development and production of "biosimilars"āanalogs of the world's best-selling (and most expensive) biotech drugs. This chart shows general expectations for the pharmaceutical sector. It reflects whether experts believe in the success of generics in biotech.
Analysts' consensus forecast for the overall market share price
Alvotech (ALVO) is a pure biosimilars player. They're an R&D company that copies complex biological drugs (like Humira). This chart, reflecting expert expectations, reflects risk appetite for them. During a downturn (pessimism), investors flee cash-burning biotechs, even if their goal (savings for medicine) is noble.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Alvotech
Alvotech is an Icelandic biotech company focused exclusively on developing and manufacturing biosimilars for the world's best-selling biologics (e.g., Humira). This chart is an indicator of their R&D pipeline. It likely aggregates their clinical trial successes, regulatory approvals, and sales partnerships.
AKIMA Market Segment Index - Pharma other
Alvotech (ALVO) is a pure-play biosimilar developer; the Icelandic company specializes in creating high-quality copies of complex biologic blockbusters (e.g., Humira clones). This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does Alvotech's niche (biosimilar) R&D model differentiate it from the average pharma company?
The AKIM Index for the overall market
Alvotech is an Icelandic biotech company. The company specializes in developing biosimilars (generics) for complex blockbusters (such as Humira). This is a high-risk scientific bet. This chart, which reflects the market average, is an indicator of risk appetite. It reveals the macro backdrop, which is critical for funding such companies.
